The field of hematopathology has undergone a rapid evolution, transitioning beyond conventional microscopy and immunophenotype-based classifications to incorporate cytogenetics, molecular data, and next-generation sequencing (NGS). ARUP Laboratories employs a unique, consensus-driven methodology to analyze data, ensuring prompt and precise results for clinicians and patients.

Weekly departmental meetings facilitate in-depth discussions on challenging cases within the Hematopathology department. Subject matter experts are readily available for second opinions on urgent matters, examining morphology, flow cytometry, and mutational profiles. This dedicated team, composed of hematopathologists, laboratory analysts, clinical variant scientists, and medical directors, collaborates to synthesize relevant data points and arrive at a diagnosis.

ARUP's innovative myeloid malignancies mutation and copy number variation assay utilize NGS to identify sequence variants, copy number variants (CNVs), and copy number-neutral loss of heterozygosity (CN-LOH). This panel test not only focuses on specific genes but also identifies and reports relevant CNVs spanning as low as 5 Mb across the genome. Covering the latest variants crucial for myeloid malignancies' diagnosis and classification, the test also pinpoints emerging biomarkers that can guide clinical management.

Leveraging the diverse expertise within the group, comprising a substantial team of board-certified hematopathologists with distinct areas of specialization, ARUP aims to share advancements in the hematopathology field. Recently, a webinar series was launched, featuring discussions by experts like Tracy George, MD, Chief Scientific Officer, and President of the Innovation Business Unit at ARUP, providing insights into the past, present, and future of hematopathology.

Source: aruplab.com

 

 

 

 

Report Abuse